1 |
KNHANES. Health behaviors and chronic disease statistics, 2016 [Internet]. Cheongju: Korea Centers for Disease Control and Prevention (KCDC); 2016 [cited 2019 May 18]. Available from: https://knhanes.cdc.go.kr/knhanes/sub04/sub04_03.do?classType=7.
|
2 |
Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019 ; 15(5) : 288-98.
DOI
|
3 |
Smith SR, Garvey WT, Greenway FL, Zhou S, Fain R, Pilson R, et al. Coadministration of Lorcaserin and Phentermine for weight management: A 12-week, randomized, pilot safety study. Obesity (Silver Spring). 2017 ; 25(5) : 857-65.
DOI
|
4 |
Jo GW, Ok JM, Kim SY, Lim YW. Review on the efficacy and safety of Mahuang and ephedrine in the treatment of obesity -Focused on RCT-. Korean J Med. 2017 ; 38(3) : 170-84.
DOI
|
5 |
Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. 2007 ; 132(6) : 2087-102.
DOI
|
6 |
Seo MH, Lee WY, Kim SS, Kang JH, Kang JH, Kim KK, et al. 2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea. J Obes Metab Syndr. 2019 ; 28(1) : 40-5.
DOI
|
7 |
Kim MK, Kim CS. Recent advances in anti-obesity agents. Korean J Med. 2018 ; 93(6) : 501-8.
DOI
|
8 |
Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000 ; 9(2) : 160-7.
DOI
|
9 |
Caixas A, Albert L, Capel I, Rigla M. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther. 2014 ; 8 : 1419-27.
|
10 |
Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017 ; 3(1) : 3-14.
DOI
|
11 |
Brashier DB, Sharma AK, Dahiya N, Singh SK, Khadka A. Lorcaserin: A novel antiobesity drug. J Pharmacol Pharmacother. 2014 ; 5(2) : 175-8.
DOI
|
12 |
Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2018 ; 6(3) : 237-48.
DOI
|
13 |
Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord. 2001 ; 25(7) : 1095-9.
DOI
|
14 |
Magkos F, Kavouras SA. Caffeine and ephedrine: physiological, metabolic and performance-enhancing effects. Sports Med. 2004 ; 34(13) : 871-89.
DOI
|
15 |
White LM, Gardner SF, Gurley BJ, Marx MA, Wang PL, Estes M. Pharmacokinetics and cardioVAScular effects of ma-huang (Ephedra sinica) in normotensive adults. J Clin Pharmacol. 1997 ; 37(2) : 116-22.
DOI
|
16 |
Shannon JR, Gottesdiener K, Jordan J, Chen K, Flattery S, Larson PJ, et al. Acute effect of ephedrine on 24-h energy balance. Clin Sci (Lond). 1999 ; 96(5) : 483-91.
DOI
|
17 |
Song YK, Lim HH. Clinical application of Ma Huang in the obesity treatment. J Korean Med Obes Res. 2007 ; 7(1) : 1-7.
|
18 |
Kim HJ, Han CH, Lee EJ, Song YK, Shin BC, Kim YK. A clinical practice guideline for Ma-huang (Ephedra sinica) prescription in obesity. J Korean Med Obes Res. 2007 ; 7(2) : 27-37.
|